• Home
  • Media
  • Sitemap
  • About Us
    • The company
      • Brief Profile
      • Vision
      • Mission 2013
      • Key Milestones
      • Board of Directors
      • Key Management Team
    • Parabolic Drugs in News
    • Media Gallery
  •  Our Business
    • CRAMS
      • Infrastructure
      • Capabilities
      • Our Business Model
      • Why PDL?
      • Contact CRAMS Division
    • APIs
      • Segments
      • Manufacturing Facilities
      • Our Products
      • Accreditations
      • Contact us for APIs
    • R & D
      • R&D Centre, Barwala
      • R&D Lab, Derabassi
      • IPR,QA & QC
  •  Global Presence
    • Market Presence
    • Regulatory Affairs
    • Business Opportunities
      • Contract Research
      • Contract manufacturing
      • Strategic tieups for Global Marketing
  • Human Resources
    • HR at PDL
      • HR Vision
      • HR Goals
    • Work with us
      • Current Openings
      • Upload your CV
  • CSR
    • CSR Initiatives
    • Environmental Concern
    • Health and Safety
  • Investor Relations
    • MD's Address
    • Corporate Governance
    • latest Financial Results
    • Key Financial Indicators
    • Share Holding Pattern
    • Annual Reports
    • Track PDL's Share
    • Research Reports on PDL
    • Contact IR
  • Contact us

Parabolic Drugs Limited(PDL) , founded in 1996, is engaged in the manufacture – including contract manufacture – of APIs and API intermediates. In the year 2011, the company has stepped up in the value chain by foraying into the domestic formulations.

Today PDL has four facilities, three state of the art manufacturing plants at Derabassi, Chachhrauli and Panchkula for over 50 API and API intermediates across antibiotics and non –antibiotic therapies and a Custom Synthesis and R&D centre at Barwala, Haryana.

The company is surging ahead with the right set of drivers –backward and forward integration, world class infrastructure, R&D strengths, diversified product basket across different therapeutic segments and Intellectual Property Rights in the form of DMFs, and Patents for novel processes.

 

 

  •      

Our Profile

From a small contract manufacturer to a reliant partner for the innovator companies

Read more

 

Analyst Corner

Latest News

Parabolic Drugs initiates production at its non antibiotic facility

Parabolic Drugs’ 9M FY12 sales up 54.39% to Rs 719.51 crore,Net Profit up 13.66% to Rs. 42.39 Crore

Parabolic Drugs H1 FY 12 sales up by 39.49% to 420.66 Crores

Unaudited Financial Results for the Quarter ended September 30th,2011

Unaudited Financial Results for the Quarter ended June 30th,2011

Parabolic Drugs get Japanese nod for bulk drugs supplies

Unaudited Financial Results for the Quarter ended March 31st, 2011

Parabolic Drugs receives Certificate of Suitability for Cefixime Molecule from EU

Parabolic Drugs' 9M FY11 net profit up 65.6% to Rs. 37.30Cr,Sales up by 24.4%

Unaudited Financial Results for the Quarter ended December 31st, 2010

PDL's Net Profit up by 163.65% in Q2FY11

Unaudited Financial Results for the Quarter ended September 30th , 2010

Notice to the Fourteenth Annual General Meeting

Download Annual Report 2009-2010

Unaudited Financial Results for the Quarter ended June 30th , 2010

PDL now compliant with EU-GMP

Parabolic Drugs Limited gets listed on BSE and NSE

FY10 Results Declared




Parabolic Drugs Limited © 2010 | About Us | Contact us | Sitemap |
Privacy Policy